Two Onc Docs

Get ready to ace your hematology questions! Explore essential insights on disorders like aplastic anemia and the intricacies of multiple myeloma diagnosis and management. Delve into myelodysplastic syndrome with a case study that highlights crucial testing. Learn about vitamin B12 deficiency and management strategies for acute promyelocytic leukemia. Finally, unpack bleeding disorders and the critical aspects of transfusion reactions, all with practical tips for your upcoming boards!

This podcast covers infusion reactions in hematology and oncology, including symptoms, treatments, and common drugs causing reactions. They discuss hypersensitivity types, management strategies, and specific drugs like taxanes, platinums, and monoclonal antibodies. The episode provides insights on monitoring, consulting specialists, and guidelines for re-challenging patients.

This podcast delves into high-yield topics on oncologic emergencies for new fellows and residents, covering brain metastases, hypercalcemia, cord compression, and SVC syndrome. They discuss management strategies like steroids, fluids, bisphosphonates, and RANK L inhibitors, emphasizing the importance of timely interventions for optimal patient care.

Dr. Spigel presents the ADRIATIC trial at ASCO 2024 focusing on Durvalumab in LS-SCLC. Topics include staging imaging, treatment approaches, trial results with improved outcomes, and future trials in small cell lung cancer space.

Dr Shikha Jain, founder of Women in Medicine & GI oncologist, shares tips for new doctors & attendings. Topics include teamwork in hospitals, importance of self-care, delivering bad news, continuous learning in medicine, essential tips for new doctors & attendings, and guidance for those in oncology.

Dr. Catherine Lai from UPenn discusses AML treatment options, including chemotherapy regimens based on core binding factors, variations in toxicity, and advancements like Gemtuzumab. She also explores recovery strategies, repeatable marrow biopsies, and different treatment approaches based on risk categories and patient fitness levels. The podcast ends with key takeaways on AML diagnosis criteria, induction regimens, specific treatment options for mutations, and the importance of seeking feedback.

Dr. Catherine Lai discusses AML classification, genetic mutations, and risk factors. Topics include treatment-related factors, hereditary myeloid malignancies, and managing leukostasis and tumor lysis syndrome in leukemia.

The podcast dives into the groundbreaking LAURA trial, showcasing how osimertinib post-chemoradiotherapy benefits patients with unresectable stage III EGFR-mutated NSCLC. It highlights advancements in staging and treatment, particularly the significance of the PACIFIC trial. Key findings reveal improved survival rates for patients on maintenance therapy. Discussions also cover the challenges of toxicity and indefinite treatment amidst unclear biomarkers, alongside the trial’s superiority over previous standards, reshaping treatment strategies for lung cancer.

Dr. Michael Atkins, a leading authority in metastatic melanoma and first author of the pioneering DREAMseq trial, delves into cutting-edge treatment options. He shares an inspiring case of an elderly patient and how immunotherapy can lead to rapid tumor regression. Discussion includes the impact of advanced therapies like BRAF-MEK inhibitors and the new Relatlimab-Nivolumab combination. Insights on treating brain metastases emphasize the need for teamwork in decision-making. Atkins also covers strategies for various melanoma subtypes and offers advice for budding oncologists.

Dr. Michael Atkins, a renowned expert and deputy director of the Georgetown Lombardi Comprehensive Cancer Center, discusses the latest in localized melanoma treatment. Breakthroughs in immunotherapy and targeted therapies are highlighted, showcasing improved survival rates. He dives into the critical staging process, emphasizing tumor thickness and lymph node involvement. The conversation also covers the effectiveness of neoadjuvant therapies like Pembrolizumab and the potential of oncolytic viruses in melanoma treatment, offering a glimpse into future clinical trials.